Co-founded by Partners Kenneth Melani, M.D., the former president and CEO of Highmark Inc., and James M. Nolan, CEO of several life sciences companies, the fund targets companies in the pharmaceutical, device, medical service, and diagnostics spaces.

Other team members include Michael Fare, who serves as Chief Operating and Technical Officer; and Joseph Donnelly, who serves as Chief Financial Officer.

The firm also announced its first acquisition of a global contract research organization (CRO) rebranded as InClinica as well as a significant investment in SkinJect, a novel method to treat skin cancer.